| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.7 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.7 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.7 |